Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms.

Gulati R, Cheng HH, Lange PH, Nelson PS, Etzioni R.

Cancer Epidemiol Biomarkers Prev. 2017 Feb;26(2):222-227. doi: 10.1158/1055-9965.EPI-16-0434.

PMID:
27742670
2.

Changes of Socio-demographic data of clients seeking genetic counseling for hereditary breast and ovarian cancer due to the "Angelina Jolie Effect".

Staudigl C, Pfeiler G, Hrauda K, Renz R, Berger A, Lichtenschopf R, Singer CF, Tea MK.

BMC Cancer. 2016 Jul 8;16:436. doi: 10.1186/s12885-016-2472-1.

3.

Experience with Bilateral Risk-Reducing Mastectomy for an Unaffected BRCA Mutation Carrier.

Maeshima Y, Oseto K, Katsuragi R, Yoshimoto Y, Takahara S, Yamauchi A.

J Breast Cancer. 2016 Jun;19(2):218-21. doi: 10.4048/jbc.2016.19.2.218.

4.

Adherence to Recommended Risk Management among Unaffected Women with a BRCA Mutation.

Buchanan AH, Voils CI, Schildkraut JM, Fine C, Horick NK, Marcom PK, Wiggins K, Skinner CS.

J Genet Couns. 2017 Feb;26(1):79-92. doi: 10.1007/s10897-016-9981-6.

PMID:
27265406
5.

Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortality.

Evans DG, Harkness EF, Howell A, Wilson M, Hurley E, Holmen MM, Tharmaratnam KU, Hagen AI, Lim Y, Maxwell AJ, Moller P.

Hered Cancer Clin Pract. 2016 Apr 14;14:8. doi: 10.1186/s13053-016-0048-3.

6.

Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers.

Menkiszak J, Chudecka-Głaz A, Gronwald J, Cymbaluk-Płoska A, Celewicz A, Świniarska M, Wężowska M, Bedner R, Zielińska D, Tarnowska P, Jakubowicz J, Kojs Z.

J Ovarian Res. 2016 Feb 29;9:11. doi: 10.1186/s13048-016-0220-4.

7.

Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis.

Phi XA, Saadatmand S, De Bock GH, Warner E, Sardanelli F, Leach MO, Riedl CC, Trop I, Hooning MJ, Mandel R, Santoro F, Kwan-Lim G, Helbich TH, Tilanus-Linthorst MM, van den Heuvel ER, Houssami N.

Br J Cancer. 2016 Mar 15;114(6):631-7. doi: 10.1038/bjc.2016.32.

8.

The Angelina Jolie Effect in Jewish Law: Prophylactic Mastectomy and Oophorectomy in BRCA Carriers.

Grossman SG.

Rambam Maimonides Med J. 2015 Oct 26;6(4). doi: 10.5041/RMMJ.10222.

9.

Economic Evaluation Alongside a Clinical Trial of Telephone Versus In-Person Genetic Counseling for BRCA1/2 Mutations in Geographically Underserved Areas.

Chang Y, Near AM, Butler KM, Hoeffken A, Edwards SL, Stroup AM, Kohlmann W, Gammon A, Buys SS, Schwartz MD, Peshkin BN, Kinney AY, Mandelblatt JS, Chang Y, Near AM, Butler KM, Hoeffken A, Edwards SL, Stroup AM, Kohlmann W, Gammon A, Buys SS, Schwartz MD, Peshkin BN, Kinney AY, Mandelblatt JS.

J Oncol Pract. 2016 Jan;12(1):59, e1-13. doi: 10.1200/JOP.2015.004838.

10.

High Satisfaction and Low Distress in Breast Cancer Patients One Year after BRCA-Mutation Testing without Prior Face-to-Face Genetic Counseling.

Sie AS, Spruijt L, van Zelst-Stams WA, Mensenkamp AR, Ligtenberg MJ, Brunner HG, Prins JB, Hoogerbrugge N.

J Genet Couns. 2016 Jun;25(3):504-14. doi: 10.1007/s10897-015-9899-4.

11.

The frequency of BRCA1 founder mutation c.5266dupC (5382insC) in breast cancer patients from Ukraine.

Gorodetska I, Serga S, Levkovich N, Lahuta T, Ostapchenko L, Demydov S, Anikusko N, Cheshuk V, Smolanka I, Sklyar S, Polenkov S, Boichenko O, Kozeretska I.

Hered Cancer Clin Pract. 2015 Oct 13;13:19. doi: 10.1186/s13053-015-0040-3.

12.

Intensified surveillance for early detection of breast cancer in high-risk patients.

Bick U.

Breast Care (Basel). 2015 Feb;10(1):13-20. doi: 10.1159/000375390. Review.

13.

Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality.

Munoz D, Near AM, van Ravesteyn NT, Lee SJ, Schechter CB, Alagoz O, Berry DA, Burnside ES, Chang Y, Chisholm G, de Koning HJ, Ali Ergun M, Heijnsdijk EA, Huang H, Stout NK, Sprague BL, Trentham-Dietz A, Mandelblatt JS, Plevritis SK.

J Natl Cancer Inst. 2014 Sep 24;106(11). pii: dju289. doi: 10.1093/jnci/dju289.

14.

Long-term prognosis of early-onset breast cancer in a population-based cohort with a known BRCA1/2 mutation status.

Nilsson MP, Hartman L, Idvall I, Kristoffersson U, Johannsson OT, Loman N.

Breast Cancer Res Treat. 2014 Feb;144(1):133-42. doi: 10.1007/s10549-014-2842-9.

15.

Identification, Evaluation, and Treatment of Patients with Hereditary Cancer Risk within the United States.

Cragun D, Pal T.

ISRN Oncol. 2013 Dec 22;2013:260847. doi: 10.1155/2013/260847. Review.

16.

Challenging and complex decisions in the management of the BRCA mutation carrier.

Stan DL, Shuster LT, Wick MJ, Swanson CL, Pruthi S, Bakkum-Gamez JN.

J Womens Health (Larchmt). 2013 Oct;22(10):825-34. doi: 10.1089/jwh.2013.4407. Review.

17.

Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers.

Pataky R, Armstrong L, Chia S, Coldman AJ, Kim-Sing C, McGillivray B, Scott J, Wilson CM, Peacock S.

BMC Cancer. 2013 Jul 10;13:339. doi: 10.1186/1471-2407-13-339.

18.

Establishing a program for individuals at high risk for breast cancer.

Cadiz F, Kuerer HM, Puga J, Camacho J, Cunill E, Arun B.

J Cancer. 2013 Jul 1;4(5):433-46. doi: 10.7150/jca.6481.

19.

Clinical utility gene card for: Hereditary diffuse gastric cancer (HDGC).

Oliveira C, Seruca R, Hoogerbrugge N, Ligtenberg M, Carneiro F.

Eur J Hum Genet. 2013 Aug;21(8). doi: 10.1038/ejhg.2012.247. No abstract available.

20.

Prevalence and healthcare actions of women in a large health system with a family history meeting the 2005 USPSTF recommendation for BRCA genetic counseling referral.

Bellcross CA, Leadbetter S, Alford SH, Peipins LA.

Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):728-35. doi: 10.1158/1055-9965.EPI-12-1280.

Supplemental Content

Support Center